An observational study in Autosomal Dominant Hypocalcemia, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company. Active, not recruiting at 27 sites in 13 countries. Open to participants aged Up to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company (part of BridgeBio) · Observational
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.
The ADH1 and ADH2 DMS is designed to better understand the disease burden of ADH1 and ADH2, how participants with ADH1 or ADH2 are managed with standard of care practices in a real-world setting, and how standard of care treatment impacts ADH1 and ADH2 symptoms.
The study will include adult and pediatric participants with a confirmed clinical diagnosis of ADH1 or ADH2. Each participant's data will be collected over a period of up to 5 years. In addition, retrospective (or past) data will be collected.
98 studies on the registry are indexed under Hypocalcemia; 16 are open to participants now.
This study's enrollment of 95 is below the median of 123 across 29 observational studies indexed under Hypocalcemia.
Browse Hypocalcemia studies →Calcilytix Therapeutics, Inc., a BridgeBio company is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligible participants include children (birth to 17 years) and adults (18 - 90 years) with ADH1 or ADH2 as determined by an activating variant of CASR in ADH1 or GNA11 in ADH2.
Key Inclusion Criteria:
Note: Acceptable documentation includes CASR or GNA11 genetic analysis report. If no prior documented CASR or GNA11 gene variant or variant of uncertain significance, potential participants can undergo CASR and GNA11 gene variant analysis at Screening.
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with ADH1 or ADH2. No investigational product will be administered to participants in this study. Participants will only receive standard of care (SoC) treatment as directed by the participants' treating physicians.
Blood Calcium Homeostasis
Time frame: Up to 60 months
Phosphorus Homeostasis
Time frame: Up to 60 months
Magnesium Homeostasis
Time frame: Up to 60 months
Intact Parathyroid Hormone (iPTH) Homeostasis
Time frame: Up to 60 months
Mineral Homeostasis as Assessed by 1,25-dihydroxyvitamin D Homeostasis
Time frame: Up to 60 months
Urine Calcium Homeostasis
Time frame: Up to 60 months
Urine Phosphorus Homeostasis
Time frame: Up to 60 months
Urine Magnesium Homeostasis
Time frame: Up to 60 months
Blood Creatinine Levels
Time frame: Up to 60 months
Estimated Glomerular Filtration Rate (eGFR)
Time frame: Up to 60 months
Number of Participants With Nephrocalcinosis and Nephrolithiasis as Assessed by Renal Ultrasound
Time frame: Up to 60 months
Bone Mineral Density as Assessed by Dual-Energy X-Ray Absorptiometry (DXA)
Time frame: Up to 60 months
Change from Baseline in 36-Item Short Form Health Survey (SF-36v2) Physical Component Score and Mental Component Score in Participants ≥ 16 years
Time frame: Up to 60 months
Change from Baseline in 10-Item Short-Form 10 Healthy Survey for Children (SF-10) Score in participants ≥ 6 years and <16 years
Time frame: Up to 60 months
Number of Participants Receiving One or More ADH1/2 Treatment Regimens
Time frame: Up to 60 months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Calcilytix Therapeutics, Inc., a BridgeBio company →